Starving the Fire: Two Years of Mild Calorie Restriction Switches Off an Ancient Immune Alarm in Human Blood
Two years of modest calorie restriction (a prescribed 25 percent cut that participants actually sustained at about 14 percent) reshaped the plasma protein landscape of 42 healthy, non-obese adults in the CALERIE-II trial. Using an aptamer platform measuring roughly 7,000 proteins, the Yale-led team found that the single most suppressed pathway was the complement cascade, an evolutionarily ancient arm of innate immunity. The specific node that mattered was C3a, the inflammatory fragment released when complement protein C3 is cleaved, and its reduction was independent of body mass index. Working backwards into mice, the authors showed that C3a rises with age, that visceral fat rather than the liver is the dominant site of this age-related C3 cleavage, and that the cells responsible are a non-senescent subset of fat-resident macrophages signaling to themselves through C3a and its receptor via ERK. Injecting a C3a-neutralizing antibody directly into the visceral fat of 20-month-old mice reduced inflammatory markers within three days. Two independent long-lived mouse models converged on the same axis.
For a century, complement has been filed away as the immune system’s demolition crew: a cascade of blood proteins that punches holes in bacteria and tags debris for disposal. This paper argues it is also a dial on how fast we inflame as we age, and that eating less turns that dial down.
The starting material is unusually good. CALERIE-II is the only randomized controlled trial of sustained calorie restriction in healthy, non-obese humans. Participants were asked to cut intake by 25 percent for two years and managed about 14 percent, losing roughly 10 percent of body weight. The Yale group took plasma from 42 of them at baseline and at two years and ran it across an assay measuring about 7,000 proteins.
The expected findings showed up: leptin and fatty acid binding proteins down, adiponectin up, growth hormone receptor and C-reactive protein down. The unexpected finding was what topped the list of suppressed pathways. Not metabolism. Complement.
Complement runs through three entry routes that all funnel into one bottleneck, protein C3. Cleaving C3 yields C3b, which is useful, and C3a, which is inflammatory. Restriction reduced components across all three entry routes, and critically it reduced C3a and the C3a-to-C3 ratio without reducing total C3. That distinction matters. It was not simply that thinner people make less complement. Most complement proteins the team measured did track with body mass index; C3a did not.
The mouse work supplies the mechanism and one genuine surprise. Since 1969 the liver has been treated as the body’s C3 factory. In aged mice, the liver showed almost no change. Visceral fat did, dramatically. The cells doing the cleaving were age-associated macrophages that, notably, were not senescent. They lacked the usual senescence markers. This is a direct challenge to the popular framing that senescent cells are the engine of inflammaging, at least for this pathway.
Those macrophages then listen to their own output: C3a binds their C3a receptor, activates ERK, and drives interleukin-1 beta and interleukin-6. Neutralizing C3a inside the fat pad of aged mice broke the loop in three days.
The catch is scope. No animal in this study was followed for lifespan. Nothing here shows that blocking C3a makes anything live longer. What it shows is a plausible, druggable node, and an FDA-approved C3 inhibitor already exists for other indications.
Actionable Insights
Sustained moderate caloric restriction provides potent anti-inflammatory benefits in humans. A 14% reduction in daily caloric intake over two years reduces circulating C3a levels and cuts systemic C-reactive protein (CRP) by 45.9% (an absolute drop from 1.59 mg/dL to 0.86 mg/dL; standardized effect size Cohen’s d = 0.65, indicating a moderate-to-large benefit). It also reduces circulating tumor necrosis factor-alpha (TNF-alpha) by 16.0% (Cohen’s d = 0.98, a large effect) and reduces fat mass by 21.4% (an absolute reduction of 5.22 kg; Cohen’s d = 2.06, a very large effect).
Visceral fat serves as an active inflammatory pacemaker rather than passive lipid storage. Interventions that reduce visceral adiposity directly diminish the expansion of age-associated macrophages and halt downstream autocrine complement signaling.
For longevity therapeutics, targeting the C3a-C3AR1 pathway offers a pharmacological strategy to replicate the immunometabolic benefits of dietary restriction. Clinically available complement inhibitors (such as pegcetacoplan) and investigational candidates (such as AMY-101) represent potential candidates for repurposing trials targeting inflammaging, provided that systemic immune defense against acute bacterial infections is carefully preserved.
Context and Source
- Open Access Paper: Exoproteome of calorie-restricted humans identifies complement deactivation as an immunometabolic checkpoint reducing inflammaging
- Lead institution: Yale School of Medicine (Departments of Pathology, Immunobiology, Comparative Medicine, and the Yale Center for Research on Aging), New Haven, Connecticut. Collaborating institutions: Washington University School of Medicine (St. Louis), UT Southwestern Medical Center (Dallas), Pennington Biomedical Research Center (Baton Rouge)
- Country: United States
-
Journal: Nature Aging, Volume 6, May 2026
Impact evaluation: The impact score of this journal is 25.0 (2025 two-year Journal Impact Factor), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.
Biomarker Data & Effect Size Extraction
| Cohort & Outcome | Baseline / Control | Intervention / Aged | Relative Change (%) | Absolute Change | Standardized Effect Size (Cohen’s d) | Statistical Significance | Confidence |
|---|---|---|---|---|---|---|---|
| Human CALERIE (2-Yr CR) | |||||||
| Serum CRP (mg/dL) PDF | 1.59 +/- 0.43 | 0.86 +/- 0.18 | -45.9% | -0.73 mg/dL | d = 0.65 (Moderate) | p = 0.048 | High |
| Serum Leptin (ng/mL) | 20.25 +/- 2.64 | 10.44 +/- 1.46 | -48.4% | -9.81 ng/mL | d = 1.34 (Very Large) | p < 0.001 | High |
| Serum TNF-alpha (pg/mL) | 3.06 +/- 0.15 | 2.57 +/- 0.14 | -16.0% | -0.49 pg/mL | d = 0.98 (Large) | p = 0.004 | High |
| Total Fat Mass (kg) | 24.36 +/- 0.72 | 19.14 +/- 0.72 | -21.4% | -5.22 kg | d = 2.06 (Very Large) | p < 0.001 | High |
| Adipose OrganAge Gap (z-score) | 0.28 +/- 0.21 | -0.22 +/- 0.19 | -178.6% | -0.50 z-units | d = 0.49 (Moderate) | p = 0.032 | Medium |
| Mouse In Vivo Anti-C3a (3-Day) | |||||||
| Visceral Fat p-ERK/ERK Ratio | 1.05 +/- 0.08 | 0.42 +/- 0.05 | -60.0% | -0.63 AU | d = 2.45 (Very Large) | p = 0.003 | High |
| Serum IL-1beta (pg/mL) | 20.1 +/- 2.1 | 13.1 +/- 1.4 | -34.8% | -7.0 pg/mL | d = 1.15 (Large) | p = 0.043 | Medium |
| Serum MCP-1 (pg/mL) | 235.0 +/- 24.0 | 153.2 +/- 16.5 | -34.8% | -81.8 pg/mL | d = 1.20 (Large) | p = 0.039 | Medium |
| Total ATMs (% gated) | 54.8 +/- 3.5 | 37.9 +/- 2.8 | -30.8% | -16.9% | d = 1.48 (Large) | p = 0.014 | High |
| M2-like ATMs (% gated) | 18.2 +/- 1.6 | 26.3 +/- 1.4 | +44.5% | +8.1% | d = 1.55 (Large) | p = 0.010 | High |
| Ly6C+ Monocytes (% gated) | 15.4 +/- 1.5 | 8.2 +/- 1.2 | -46.8% | -7.2% | d = 1.46 (Large) | p = 0.014 | High |
Novelty
-
Establishes the complement cascade, specifically the C3a-C3AR1 axis, as the top downregulated exoproteomic pathway during human caloric restriction.
-
Decouples the reduction of C3a from weight loss and BMI changes, identifying it as an active regulatory checkpoint rather than a secondary consequence of fat mass loss.
-
Pinpoints non-senescent visceral adipose tissue macrophages as the primary cellular source driving age-related complement activation.
-
Demonstrates that short-term direct neutralization of C3a in visceral fat is sufficient to rewire local immune architecture (increasing M2-like macrophages while decreasing inflammatory monocytes and total macrophages) and lower systemic inflammatory cytokines.
Critical Limitations & Translational Uncertainty
-
Invasive Delivery Route: The in vivo mouse experiment utilized direct intra-adipose microinjections (4 ug per depot) requiring open surgical exposure of visceral fat. This limits direct clinical translation until targeted visceral adipose delivery technologies (e.g., lipid nanoparticle conjugates or depot-homing peptides) are validated.
[Confidence: High] -
Acute Duration: The rodent neutralization study evaluated outcomes at a single 3-day timepoint following a single injection. Long-term durability, potential target up-regulation, antibody clearance kinetics, and chronic immunometabolic remodeling remain unaddressed.
[Confidence: High] -
Inconclusive Systemic Complement Depletion: While intra-adipose antibody delivery suppressed local ERK activation and tissue macrophage numbers, serum C3a reductions exhibited only a statistical trend (p = 0.056), and total serum C3 levels were unaffected.
[Confidence: Medium] -
Infection Vulnerability and Intracellular Complosome Risks: Systemic complement inhibition in clinical populations poses risks of severe encapsulated bacterial infections (e.g., Neisseria meningitidis, Streptococcus pneumoniae). Furthermore, non-canonical intracellular complement (the complosome) regulates homeostatic T-cell survival, nutrient transport, and efferocytosis; indiscriminate inhibition may produce off-target cellular toxicity.
[Confidence: High] -
Cohort Constraints: Human proteomics were generated from a relatively young and predominantly female cohort (mean age 38.3 years; 76.2% female) from a single study site (Pennington Biomedical), limiting generalizability to elderly, frail, or multimorbid populations.
[Confidence: Medium]
This investigation provides strong evidence that visceral adipose tissue-derived complement activation drives systemic inflammaging. While caloric restriction remains an effective behavioral intervention to deactivate this pathway, pharmacological translation via selective C3a-C3AR1 antagonism or visceral fat-targeted therapeutics represents a viable strategy for human healthspan extension.
Translation Challenges:
The intracellular complement problem. Raised by the authors themselves and the strongest theoretical objection to translation. Intracellular C3 regulates energy metabolism, lipid metabolism, cell survival and efferocytosis. Combined with the known infection risk from C3 deficiency, the therapeutic window for chronic C3 blockade in healthy aging humans is entirely unknown. Their own supplementary data note AMY-101 had low efficacy in mice and off-target effects at high dose. [Confidence: High]
The Drugs Discussed in the Paper:
The paper directly discusses two clinical-stage C3 inhibitors and one preclinical neutralizing antibody targeting the complement pathway.
| Inhibitor Name | Target Molecule | Regulatory Status | Primary Clinical Indications | Route of Administration | Key Safety Warnings & Side Effects |
|---|---|---|---|---|---|
| Pegcetacoplan(Empaveli / Syfovre / APL-2) | Complement Component C3 and C3b | FDA Approved (2021, 2023, 2025) | Paroxysmal Nocturnal Hemoglobinuria (PNH), Geographic Atrophy (AMD), C3 Glomerulopathy (C3G) | Subcutaneous infusion, Intravitreal injection | Boxed warning for fatal encapsulated bacterial infections (S. pneumoniae, N. meningitidis, H. influenzae), intraocular inflammation, conversion to wet AMD |
| AMY-101(Cp40) | Complement Component C3 | Investigational (Phase 2 completed) | Chronic Periodontitis, C3 Glomerulopathy, COVID-19 ARDS | Local intragingival injection, Systemic IV/SC | Transient local injection-site discomfort; systemic risk of impaired bacterial opsonization |
| Anti-C3a Monoclonal Antibody(Clone 3/11) | Cleaved C3a Anaphylatoxin | Preclinical Experimental Tool | Murine proof-of-concept for inflammaging, acute lung injury, thrombosis | Local intra-adipose, Intraperitoneal, IV | Surgical site trauma in depot delivery; theoretical long-term suppression of acute tissue repair |
Pegcetacoplan (Empaveli / Syfovre)
Mechanism & Molecular Profile Pegcetacoplan is a PEGylated bicyclic peptide derivative belonging to the compstatin family. It consists of two 15-amino acid cyclic peptides joined by a 40 kDa linear polyethylene glycol (PEG) chain that extends its circulatory half-life to roughly eight days. It binds symmetrically to human C3 and its active fragment C3b, sterically inhibiting both C3 convertases and C5 convertases across classical, lectin, and alternative pathways.
Regulatory Approval & Use History
- May 2021 (FDA Approval): Approved as Empaveli for the treatment of adults with Paroxysmal Nocturnal Hemoglobinuria (PNH), based on the randomized Phase 3 PEGASUS trial where it proved superior to eculizumab in elevating hemoglobin levels and reducing transfusion dependency by blocking both intravascular and extravascular hemolysis.
- February 2023 (FDA Approval): Approved as Syfovre for geographic atrophy secondary to age-related macular degeneration, following the Phase 3 DERBY and OAKS trials, which demonstrated a 17% to 22% reduction in geographic atrophy lesion growth rate over 24 months.
- July 2025 (FDA Approval): Expanded approval for adults and pediatric patients aged 12 and older with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) based on the Phase 3 VALIANT trial, achieving a 68% reduction in proteinuria.
Adverse Events & Safety Profile
- Infection Susceptibility: Carries an FDA Boxed Warning regarding life-threatening infections caused by encapsulated bacteria (Streptococcus pneumoniae, Neisseria meningitidis serogroups A, C, W, Y, and B, and Haemophilus influenzae type B). Prophylactic immunization is legally mandated at least two weeks prior to starting systemic therapy.
- Ophthalmologic Complications (Syfovre): Associated with non-infectious intraocular inflammation, infectious endophthalmitis, retinal detachment, ischemic optic neuropathy, and an elevated incidence of converting from dry to exudative (wet) macular degeneration (roughly 7% to 12% of patients).
- Systemic Complications (Empaveli): Frequent injection-site reactions (erythema, induration), diarrhea, abdominal pain, viral upper respiratory infections, and interference with silica-based laboratory coagulation assays.
AMY-101 (Cp40)
Mechanism & Molecular Profile AMY-101 is a third-generation synthetic 14-amino-acid cyclic compstatin analog (Cp40) developed by Amyndas Pharmaceuticals. It incorporates non-proteinogenic amino acids (including 1-methyl-tryptophan) to achieve sub-nanomolar binding affinity (KD≈0.5 nM) for human and non-human primate C3. As highlighted in the paper, AMY-101 exhibits extreme primate species specificity and does not bind rodent C3 effectively, rendering it largely inactive in mice and liable to off-target artifacts at supra-physiological doses in standard murine models.
Clinical Trials History
-
Periodontal Inflammation: Evaluated in a randomized, double-blind, placebo-controlled Phase 2a trial (NCT03694444) in adult patients with chronic periodontitis. Local intragingival injections administered once weekly for three weeks produced statistically significant reductions in gingival index, bleeding on probing, and tissue destruction markers (MMP-8, MMP-9) that persisted for three months post-treatment.
-
Systemic Applications: Tested in exploratory Phase 2 protocols for severe COVID-19 ARDS/systemic thromboinflammation, demonstrating rapid reduction in systemic complement activation markers and inflammatory cytokines, as well as ongoing investigations in rare kidney diseases (C3G) and PNH.
Adverse Events & Safety Profile
- Local intra-oral administration showed no serious adverse events, ulcerations, or delayed tissue healing.
- Systemic administration carries identical mechanistic liabilities to other broad C3 blockers, primarily increased risk of encapsulated bacterial sepsis if circulating C3-mediated opsonization and phagocytosis are blunted continuously.
Anti-C3a Monoclonal Neutralizing Antibody (Clone 3/11)
Mechanism & Experimental Background The authors utilized a rat monoclonal IgG2a antibody (clone 3/11, Hycult Biotech) directed specifically against the cleaved mouse C3a anaphylatoxin. Unlike upstream C3/C5 convertase blockers or compstatin analogues, this antibody selectively intercepts released C3a, preventing its binding to the C3a receptor (C3AR1) on target immune cells without interfering with C3b deposition, opsonization, phagocytosis, or downstream C5b-9 membrane attack complex formation.
History of Research Use
-
Originally described and characterized by Mastellos and colleagues in 2004 as a selective tool to decouple C3a anaphylatoxin signaling from C3b opsonization.
-
Widely utilized in preclinical rodent studies investigating ischemia-reperfusion injury, acute lung injury, complement-mediated thrombosis, and autoimmune neuroinflammation.
-
In the current study, it was applied in vivo via direct intra-adipose microinjection (4 micrograms per depot) into 20-month-old male mice, reversing ERK phosphorylation, reducing systemic IL-1beta and MCP-1 levels, and shifting adipose tissue macrophage polarization away from inflammatory subsets toward restorative M2-like phenotypes over a 3-day window.
Limitations & Translational Challenges
- The antibody is restricted to research use in animals; no humanized formulation or human clinical trial data exist.
- In vivo delivery into visceral fat required open abdominal laparotomy. Human translation would require non-invasive adipose-homing drug conjugates or selective small-molecule oral C3AR1 antagonists to bypass surgical requirements.
Targeted deactivation of C3a signaling provides an anti-inflammatory effect while preserving the membrane attack complex and upstream opsonization pathways that defend against acute bacterial infections. This makes selective downstream C3a-C3AR1 antagonism a more pharmacologically viable longevity strategy than unselective upstream complement destruction.